$500 million is a nice clip for a product viewed by many as inferior to botox and it seems as if Galderma is doing a lot of the heavy lifting. Galderma appears heavily invested in Dysport and continues to gain access to new territories. If Galderma was interested in Revance this would put them in a bit of a pickle. They either act sooner rather than later, return the Dysport rights to Ipsen, and then wait 2 full years until RT002 is approved while forgoing 2 years worth of Dysport revenue. Or they wait closer to RT002 approval and run the risk of someone else scooping up Revance and becoming a direct competitor. To make matters even more complex, Galderma might have to return rights to Restylane, Perlane, Sculptra?
In conclusion the Galderma Revance collaboration is a lot less cut and dry to me than I thought, but not much is!
News 
Market Data 
Discover 
